EUVIMEDEUVIMED entdecken
Open Access

Design, Synthesis, and Molecular Docking of Triazole‐Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis

Murat Keser, Emre Menteşe, Suleyman Ilhan iD, Mustafa Emirik, Harika Atmaca iD

Chemistry & Biodiversity · 2025-12 · 22 (12)

DOI: 10.1002/cbdv.202501775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 05.09.2025. Verfasst von Murat Keser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Izmir Tepecik Education and Research Hospital, University of Health Sciences, Izmir, Türkiye. Hauptthemen laut MEDLINE: Triazoles, Coumarins, Apoptosis, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer continues to pose a significant global health burden, highlighting the urgent need for novel chemotherapeutic agents with improved selectivity and reduced toxicity. In this study, we rationally designed and synthesized six novel amide‐bridged triazole‐coumarin hybrids ( 5a–f ) based on the known anticancer potential of both pharmacophores. The synthesized compounds were evaluated for their cytotoxicity in MCF‐7 and MDA─MB─231 breast cancer cell lines and non‐tumorigenic MCF‐10A cells. Among them, derivative 5f showed the most potent anticancer activity with minimal toxicity toward normal cells. Mechanistic studies revealed that 5f induced apoptosis by modulating Bax and Bcl─2 expression and arrested the cell cycle at the S phase via downregulation of CDK2 and Cyclin E. Molecular docking analyses confirmed its high binding affinity to CDK2 and Bcl─2, supporting its potential as a dual‐target inhibitor. These findings suggest that compound 5f is a promising lead structure for the development of selective anticancer agents targeting breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesCoumarinsApoptosisAntineoplastic AgentsMolecular Docking SimulationDrug DesignBreast NeoplasmsHumansDrug Screening Assays, AntitumorStructure-Activity RelationshipFemaleMolecular StructureCell ProliferationCell CycleDose-Response Relationship, DrugCell Line, Tumor

Stichwörter der Autor:innen

apoptosisbreast cancercell cyclemolecular dockingtriazole‐coumarin hybrid

Substanzen

TriazolesCoumarinsAntineoplastic Agentscoumarin

Autor:innen und Institutionen

  • Department of Medical Oncology, Izmir Tepecik Education and Research Hospital, University of Health Sciences, Izmir, Türkiye.
  • Department of Chemistry, Faculty of Science and Art, Recep Tayyip Erdogan University, Rize, Türkiye.
  • Department of Biology, Faculty of Engineering and Natural Sciences, Manisa Celal Bayar University, Manisa, Türkiye.

ORCID-Profile: Suleyman Ilhan, Harika Atmaca

Zitieren

APA

Keser, M., Menteşe, E., Ilhan, S., Emirik, M., & Atmaca, H. (2025). Design, Synthesis, and Molecular Docking of Triazole‐Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis. Chemistry & Biodiversity, 22(12). https://doi.org/10.1002/cbdv.202501775

Vancouver

Keser M, Menteşe E, Ilhan S, Emirik M, Atmaca H. Design, Synthesis, and Molecular Docking of Triazole‐Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis. Chemistry & Biodiversity. 2025;22(12). doi:10.1002/cbdv.202501775

BibTeX
@article{Keser2025,
  author = {Keser, Murat and Menteşe, Emre and Ilhan, Suleyman and Emirik, Mustafa and Atmaca, Harika},
  title = {Design, Synthesis, and Molecular Docking of Triazole‐Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  volume = {22},
  number = {12},
  doi = {10.1002/cbdv.202501775}
}
Kostenlos starten →